---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-073836"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:02:52.092690+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharma stockholders elect all director nominees, ratify BDO, approve equity plan, pass say-on-pay

## Summary
- All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).
- Ratification of BDO USA as auditors passed with 32.5M For, 8.3M Against, 0.8M abstain.
- 2023 Omnibus Equity Incentive Plan approved with 14.4M For, 12.0M Against, 0.3M abstain.
- Advisory say-on-pay proposal passed with 14.2M For, 12.2M Against, 0.4M abstain.

## SEC filing metadata
- accession: 0001104659-23-073836
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/tm2319442d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-073836
- JSON: https://secwatch.observer/filing/0001104659-23-073836.json
- Plain text: https://secwatch.observer/filing/0001104659-23-073836.txt

## Key facts
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company's named executive officers at the 2023-06-22 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: To approve, on an advisory basis, the compensation of the Company’s named executive officers, referred to as “say-on-pay.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Election of seven directors at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: To elect the seven (7) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified including Gary S. Jacob, Robert Foster, John P. Brancaccio, Timothy Block, Peter Wijngaard, Anand Reddi and Kaouthar Lbiati.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of BDO USA, LLP as the Company's independent auditors for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: To ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm
- Shareholder Votes
  Hepion Pharmaceuticals, Inc. shareholders approved Approve the Company's 2023 Omnibus Equity Incentive Plan at the 2023-06-22 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: To approve the Company’s 2023 Omnibus Equity Incentive Plan.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.